PDF(Pubmed)
Abstract：
OBJECTIVE: Laser endoscopic enucleation of the prostate (EEP) for benign prostatic obstruction has become increasingly prevalent worldwide. Considering the medical cost-savings and concomitantly fewer nosocomial infections, the feasibility of same-day postoperative discharge of patients who have undergone laser EEP in terms of its safety and effectiveness has become a subject matter of growing interest. We aimed to review those studies focussing on day-case surgery (DCS) in patients undergoing laser EEP.
METHODS: A systematic search was conducted using PubMed-MEDLINE and Web of Science databases until October 2022 with the following search terms: \"same day discharge AND laser enucleation of the prostate\", \"day-case AND laser enucleation of the prostate\", \"same day surgery AND laser enucleation of the prostate\" and \"one day surgery AND laser enucleation of the prostate\" by combining PICO (population, intervention, comparison, outcome) terms. We identified 15 eligible studies.
RESULTS: While 14 of the studies focussed on holmium laser EEP, one focused on thulium laser vapoenucleation of the prostate. We observed an improvement in functional parameters in all studies we reviewed, and DCS success and readmission rates ranged between 35.3-100% and 0-17.8%, respectively. The complication rates varied between 0 and 36.7%, most of the complicatons were Clavien-Dindo (CD) I and II. CD ≥ III complications did not significantly differ between same day discharge (SDD) and non-SDD groups in the studies.
CONCLUSIONS: Laser EEP is feasible and promising DCS treatment option delivering improved functional parameters compared to baseline values, and lower perioperative complication and readmission rates in certain patients.
METHODS: A systematic search was conducted using PubMed-MEDLINE and Web of Science databases until October 2022 with the following search terms: \"same day discharge AND laser enucleation of the prostate\", \"day-case AND laser enucleation of the prostate\", \"same day surgery AND laser enucleation of the prostate\" and \"one day surgery AND laser enucleation of the prostate\" by combining PICO (population, intervention, comparison, outcome) terms. We identified 15 eligible studies.
RESULTS: While 14 of the studies focussed on holmium laser EEP, one focused on thulium laser vapoenucleation of the prostate. We observed an improvement in functional parameters in all studies we reviewed, and DCS success and readmission rates ranged between 35.3-100% and 0-17.8%, respectively. The complication rates varied between 0 and 36.7%, most of the complicatons were Clavien-Dindo (CD) I and II. CD ≥ III complications did not significantly differ between same day discharge (SDD) and non-SDD groups in the studies.
CONCLUSIONS: Laser EEP is feasible and promising DCS treatment option delivering improved functional parameters compared to baseline values, and lower perioperative complication and readmission rates in certain patients.
摘要：
目的：激光内镜下前列腺摘除术（EEP）治疗良性前列腺梗阻在世界范围内越来越普遍。考虑到医疗成本的节约和随之而来的更少的医院感染，就安全性和有效性而言,接受激光EEP的患者在术后当天出院的可行性已成为人们日益关注的主题.我们旨在回顾那些专注于激光EEP患者日间手术（DCS）的研究。
方法：使用PubMed-MEDLINE和WebofScience数据库进行了系统搜索，直到2022年10月：“同一天放电和前列腺激光摘除”，“日间病例和激光前列腺摘除术”，“同一天手术和前列腺激光摘除”和“一天手术和前列腺激光摘除”通过结合PICO（人口，干预，比较,结果)条款。我们确定了15项符合条件的研究。
结果：虽然14项研究集中在钬激光EEP上，其中一个集中在thu激光前列腺摘除术上。在我们回顾的所有研究中，我们观察到功能参数的改善，DCS成功率和再入院率在35.3-100%和0-17.8%之间，分别。并发症发生率在0至36.7%之间，大多数复杂的是Clavien-Dindo（CD）I和II。研究中，同一天出院（SDD）和非SDD组之间的CD≥III并发症没有显着差异。
结论：激光EEP是可行且有前景的DCS治疗方案，与基线值相比，其功能参数得到了改善，某些患者的围手术期并发症和再入院率较低。
方法：使用PubMed-MEDLINE和WebofScience数据库进行了系统搜索，直到2022年10月：“同一天放电和前列腺激光摘除”，“日间病例和激光前列腺摘除术”，“同一天手术和前列腺激光摘除”和“一天手术和前列腺激光摘除”通过结合PICO（人口，干预，比较,结果)条款。我们确定了15项符合条件的研究。
结果：虽然14项研究集中在钬激光EEP上，其中一个集中在thu激光前列腺摘除术上。在我们回顾的所有研究中，我们观察到功能参数的改善，DCS成功率和再入院率在35.3-100%和0-17.8%之间，分别。并发症发生率在0至36.7%之间，大多数复杂的是Clavien-Dindo（CD）I和II。研究中，同一天出院（SDD）和非SDD组之间的CD≥III并发症没有显着差异。
结论：激光EEP是可行且有前景的DCS治疗方案，与基线值相比，其功能参数得到了改善，某些患者的围手术期并发症和再入院率较低。
